Loading company…
Pherecydes Pharma SA develops phage-based therapies for antibiotic-resistant bacterial infections, based in Romainville, France.
Pherecydes Pharma SA is a biopharmaceutical company developing therapies based on phage technology against antibiotic-resistant bacterial infections. Founded in 2006 and headquartered in Romainville, France, it is listed at the Series A stage and has completed 9 deals. Its most recent deal, on February 2, 2021, was an IPO raising EUR 28.14 million from 4.69 million shares at EUR 6 on Euronext Paris (ticker ALPHE). Tikehau Capital, Go Capital and Omnes Capital took minority stakes of 23.77%, 12.02% and 6.85%.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in